Transcatheter aortic valve replacement in cancer patients with chest radiation therapy: Risks and outcomes.

• DOI: 10.1200/jco.2025.43.16_suppl.e24020
• Publication Date: 2025-05-28T17:57:49Z
• Authors: Saad Farooq; Muneeb Khawar; Umad Ali; Syed Abdullah Shah; Mirza Muhammad Ha...; Awon Muhammad; Hannan Saeed; Sardar Muhammad I...; Abdul Qadeer; Mobeen Zaka Haider; Mohammad Hamza; Robert W. Kirchoff

e24020 Background: Transcatheter aortic valve replacement (TAVR) is a widely adopted treatment for severe stenosis, but outcomes in cancer survivors with prior chest radiation therapy (C-XRT) remain uncertain. This study compares the clinical of TAVR between patients history C-XRT and those without exposure (control group). Methods: Patients were compared to control group evaluate key endpoints. For each endpoint, odds ratios (OR) 95% confidence intervals (CI) determined, heterogeneity was analyzed using I² statistic. A p-value <0.05 considered statistically significant. Results: Nine studies included meta-analysis, encompassing 3083 8891 patients. showed significantly higher long-term mortality (OR 1.84, CI [1.08, 3.13], p=0.02) controls. Other outcomes, including access-related vascular complications, Acute Kidney Injury, Congestive heart failure, major bleeding, need pacemaker, short-term mortality, stroke, did not demonstrate significant differences groups. Conclusions: Cancer undergoing may experience exposure. However, no observed other outcomes. These findings suggest that while viable patients, risks require further investigation optimize patient selection management strategies. Outcomes. Outcome OR Confidence Interval P value Access related complications 1.12 [0.85, 1.48] 0.43 kidney injury 0.54 [0.20, 1.50] 0.24 failure 1.38 [0.88, 2.17] 0.16 Long term 1.84 3.13] 0.02 Major bleeding 0.96 [0.78, 1.17] 0.67 Need pacemaker 1.05 1.26] 0.57 Short 1.66 [0.97, 2.84] 0.06 Stroke 1.25 [0.74, 2.11] 0.39